No Data
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target
BioCardia Analyst Ratings
Promising Outlook for BioCardia With Advancements in CardiAMP HF Program and Personalized Treatment Approach
Express News | BioCardia Inc - Results on Track for Top Line Release in Q1 2025
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
Express News | BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
No Data
No Data